TauRx Chairman to present at scientific symposium focused on advances in Alzheimer’s treatments
Date: 2.4.2014
Prof. Wischik, Chairman of TauRx Therapeutics, will present a scientific update at the 13 th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy on the company’s global Phase 3 clinical trials; its tau aggregation inhibitor, LMTX™, is aimed at halting the progression of Alzheimer’s.
ABERDEEN, Scotland, 27 March 2014 – TauRx Therapeutics Ltd, a University of Aberdeen spin-out and privately held company, announced todaythat its Chairman,Professor Claude Wischik, will be presenting at the 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy on Friday 28 th March at 10:45 a.m. In a session focusing on tau-based therapies and diagnostics for Alzheimer’s disease, Professor Wischik will describe the scientific basis for tau aggregation inhibition and provide an update on the company’s global Phase 3 clinical trials programme.
The annual international conference brings together approximately 1,500 thought leaders in neurology, old-age psychiatry, gerontology and pharmacology to discuss new targets and drugs for the treatment of Alzheimer’s disease, and novel approaches to therapy.
A pioneer in tau pathology research, Professor Wischik’s work led to the scientific discovery that the neurofibrillary tangles first identified by Alzheimer in the brains of Alzheimer’s disease patients are comprised of the microtubule-associated protein tau in the form of filamentous aggregates. This course of research began at Cambridge University in 1985 in the laboratory of Sir Martin Roth (who was the first to correlate tangles in the brain with Alzheimer’s dementia), and later with Sir Aaron Klug (Nobel Laureate). Professor Wischik subsequently established that these tau protein tangles could be dissolved with pharmaceutical agents that act as ‘tau aggregation inhibitors’. He further demonstrated a direct link between clinical dementia and tau aggregation at the biochemical level, irrespective of amyloid load in the human brain. As Chairman and Co-founder of TauRx Therapeutics, Professor Wischik has led the company to its present stage of conducting global Phase 3 clinical trials of its tau aggregation inhibitor, LMTX™, in mild to moderate Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD).
For more information about the clinical trials, patients and carers: www.alzheimersglobalstudies.net and www.ftdstudy.net.
Share this article:
